Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Depreciation & Amortization (CF) (2016 - 2017)

Bone Biologics (BBLG) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $24.0 as the latest value for Q4 2017.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 40.0% to $24.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $96.0, a 86.29% decrease, with the full-year FY2019 number at $50.0, down 47.92% from a year prior.
  • Depreciation & Amortization (CF) was $24.0 for Q4 2017 at Bone Biologics, roughly flat from $24.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $580.0 in Q1 2016 to a low of $24.0 in Q1 2017.